Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.45 USD
Change Today -0.18 / -1.08%
Volume 194.4K
LMNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMNX) Key Developments

Luminex Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Revenue Guidance for Second Quarter of 2015 and Reaffirms Revenue Guidance for 2015

Luminex Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $57.741 million compared to $56.561 million a year ago. Income from operations were of $9.693 million compared to $8.185 million a year ago. Income before income taxes was $10.387 million compared to $8.160 million a year ago. Net income was $7.453 million or $0.18 per diluted share compared to $5.966 million or $0.14 per diluted share a year ago. Net cash provided by operating activities was $10.935 million compared to $11.437 million a year ago. Purchase of property and equipment was of $8.898 million compared to $3.105 million a year ago. The Company reaffirms its 2015 annual revenue guidance of between $230 million and $236 million. As a reminder, the company will record income tax expense on profits generated in Canadian subsidiary over the near term and as a result, expect consolidated effective tax rate to be in the 25% to 35% range over the next several years, absent any other significant discrete items. In addition, the Company anticipates second quarter 2015 revenue to be between $56 million and $58 million.

Luminex Corporation to Report Q1, 2015 Results on May 04, 2015

Luminex Corporation announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 04, 2015

Luminex Corporation, Q1 2015 Earnings Call, May 04, 2015

Luminex Corporation, Q1 2015 Earnings Call, May 04, 2015

Luminex Corporation Announces Launch of the NxTAG Respiratory Pathogen Panel

Luminex Corporation announced the launch of the NxTAG Respiratory Pathogen Panel (RUO). The NxTAG Respiratory Pathogen Panel is the only respiratory assay that enables laboratories to both simultaneously detect 22 respiratory pathogens in a single closed tube system and accommodate the higher throughput required to respond to seasonal changes in demand. The NxTAG Respiratory Pathogen Panel requires only minutes of hands-on time and no upstream reagent preparation. Extracted samples are added directly to pre-plated, lyophilized reagents. The tubes are then sealed and ready for closed tube amplification and subsequent detection using the Luminex MAGPIX instrument. The innovative tube strip design offers laboratories the flexibility to manage variable sample demand by processing a single sample or up to 96 samples per run without wasting consumables or reagents. The NxTAG Respiratory Pathogen Panel total turnaround time is approximately three hours for 96 samples (excluding extraction). The accompanying SYNCT™ Software provides a comprehensive approach to data analysis and reporting, and integrates the NxTAG Respiratory Pathogen Panel easily into any laboratory. Clinical trials for the NxTAG Respiratory Pathogen Panel are in progress in the U.S.

Luminex Corporation Endorses Mix&GoTM Activation Kit of Anteo Technologies Pty Ltd

Anteo Technologies Pty Ltd. announced that to provide shareholders with the link to a blog posted by Luminex Corporation that describes the performance and benefits of using Anteo Mix&GoTM (AMG) Activation Kit for Multiplex Microspheres on the Luminex xMAP platform. In line with Anteo Technologies' product pipeline development strategy, the company launched the AMG Activation Kit for Multiplex Microspheres in December 2014 to assist users of Luminex systems to more easily transfer their existing ELISA assays onto the Luminex platform. The AMG Activation Kit also allows users to troubleshoot proteins that are difficult to attach to Luminex microspheres using other methods. As previously reported, a number of Luminex partners are now engaged with Anteo and one is engaged in a study with clinical samples that is scheduled to conclude this quarter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $16.45 USD -0.18

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $54.11 USD -0.06
Fluidigm Corp $24.71 USD -0.52
HealthStream Inc $27.72 USD +0.38
Meridian Bioscience Inc $18.27 USD -0.34
Quidel Corp $21.84 USD -0.89
View Industry Companies
 

Industry Analysis

LMNX

Industry Average

Valuation LMNX Industry Range
Price/Earnings 17.1x
Price/Sales 3.0x
Price/Book 2.1x
Price/Cash Flow 16.0x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.